GENERIC NAME formulation (Brand name®▼) for some indication

# The Pan Mersey Area Prescribing Committee recommends the prescribing of GENERIC NAME formulation (Brand name®▼), for some indication in accordance with NICE TAXXX.

## SAFETY

Do not repeat statement in box above. Only add a similar statement if extra information included as clarification. If it is a new drug, it may be useful to add some information about licensed use.

Define which specialists can prescribe. Prescribing should be retained by the specialist.

NICE technology appraisal (TA) xxx recommends GENERIC NAME formulation (Brand name®▼) as an option for treating some indication only if:

* criteria 1
* criteria 2 etc

Reference NICE guidance and any relevant local guidance also available on the same subject matter (hyperlink or ask for hyperlink to be inserted in final version). When quoting NICE guidance refer to the TA number and the date published.

Costing information - Top-line information e.g. changes in drug cost per 100,000 population, change in activity cost per 100,000 population.

### Prescribing information

Dose regimen and monitoring advice.

### Implementation notes

Arrangements for prescribing and monitoring.

### References

1. Reference 1 with hyperlink
2. Reference 2 with hyperlink